Where is Merck & Co. (MRK) Headed According to Wall Street?

Group 1 - Merck & Co., Inc. (NYSE:MRK) is recognized as one of the best affordable healthcare stocks to buy, with a Buy rating reaffirmed by Jefferies analyst Tycho Peterson and a price target set at $139.00 [1] - The company announced a historic agreement with the Trump administration to enhance the affordability and accessibility of its medicines for Americans, ensuring access to life-changing vaccines and medications at lower costs [2] - Merck plans to provide key products at affordable prices for eligible patients in the US through a direct-to-patient program, which currently includes JANUVIA, JANUMET, and JANUMET XR, offering approximately a 70% discount from the current list price [3] Group 2 - Management reported an understanding with the U.S. Department of Commerce for a three-year delay of Section 232 tariffs, enabling Merck to invest in reshoring manufacturing for American patients [4] - Merck is a biopharmaceutical company focused on advancing the treatment and prevention of diseases in both animals and humans, with its Pharmaceutical segment offering vaccines and human health products [5]